Our study revealed that serum NY‐ESO‐1 and p53 antibodies were positive in 12.6% and 18.1% of patients with gastric cancer, respectively, and the combination of NY‐ESO‐1 and p53 antibody responses to general tumor markers CEA and CA19‐9 increased the diagnostic accuracy of gastric cancer. This evidence concerns the gene CEACAM5 and gastric cancer.